Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling

Documenti analoghi

• Identification of a Safe and Tolerable Carbamazepine Dosing Paradigm that Facilitates Effective Evaluation of CYP3A4 Induction
  di: Amita Datta‐Mannan, et al.
  Pubblicazione: (2024)
• Age‐Dependent Abundance of CYP450 Enzymes Involved in Metronidazole Metabolism: Application to Pediatric PBPK Modeling
  di: Md Masud Parvez, et al.
  Pubblicazione: (2024)
• PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors
  di: Kenichi Umehara, et al.
  Pubblicazione: (2024)
• Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form
  di: Vivek Purohit, et al.
  Pubblicazione: (2024)
• Dose Optimization Informed by PBPK Modeling: State‐of‐the Art and Future
  di: Karen Rowland Yeo, et al.
  Pubblicazione: (2024)